MedPath

Benefits of Phosphocreatine use during Tetralogy of Fallot repair in childre

Phase 3
Conditions
Health Condition 1: null- Children with Tetralogy of Fallot aged 6 months to 14 years undergoing intracardiac repair
Registration Number
CTRI/2018/01/011594
Lead Sponsor
GKeerthi
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

all cases undergoing intracardiac repair for TOF

Exclusion Criteria

1. Emergency cases

2. TOF with Absent pulmonary valve

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath